Optimizing the management of benign prostatic hyperplasia

Therapeutic Advances in Urology

Volumn 4, Issue 2, 2012, Pages 77-83

  Elterman, Dean S ^a   Barkin, Jack ^b   Kaplan, Steven A ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

5 alpha reducinhibitors; alpha blockers; anticholinergics; benign prostatic hyperplasia; LUTS

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TERAZOSIN;

ASTHENIA; DIET SUPPLEMENTATION; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; NOCTURIA; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RHINITIS; SABAL; SEXUAL DYSFUNCTION; SMOOTH MUSCLE TONE; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL INCISION OF THE PROSTATE; URINALYSIS; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URTICA DIOICA;

EID: 84859122972     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212437361     Document Type: Review

References (30)

1. Abrams P. Chapple C. Khoury S. Roehrborn C. De la Rosette J. (2009) Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 181: 1779–1787.
2. Abrams P. Kaplan S. De Koning Gans H.J. Millard R. (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999–1004; discussion 1004.
3. Andersson K.E. (2011) Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 59: 377–386.
4. Barkin J. (2011a) Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol 18(Suppl.): 14–19.
5. Barkin J. (2011b) Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence 5: 483–490.
6. Barkin J. Guimaraes M. Jacobi G. Pushkar D. Taylor S. Van Vierssen Trip O. B. (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 a-reductase inhibitor dutasteride. Eur Urol 44: 461–466.
7. Barkin J. Roehrborn C.G. Siami P. Haillot O. Morrill B. Black L. Montorsi F. (2009) Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 103: 919–926.
8. Barry M.J. Williford W.O. Chang Y. Machi M. Jones K.M. Walker-Corkery E. Lepor H. (1995) Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154: 1770–1774.
9. Bushman W. (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36: 403–415, v.
10. Clark R.V. Hermann D.J. Cunningham G.R. Wilson T.H. Morrill B.B. Hobbs S. (2004) Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 a-reductase inhibitor. J Clin Endocrinol Metab 89: 2179–2184.
11. Debruyne F.M. (2000) Alpha blockers: are all created equal? Urology 56: 20–22.
12. Debruyne F. Barkin J. Van Erps P. Reis M. Tammela T.L. Roehrborn C. (2004) Efficacy and safety of long-term treatment with the dual 5 a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46: 488–494; discussion 495.
13. Djavan B. Waldert M. Ghawidel C. Marberger M. (2004) Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 14: 45–50.
14. Donatucci C.F. Brock G.B. Goldfischer E.R. Pommerville P.J. Elion-Mboussa A. Kissel J.D. Viktrup L. (2011) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 107: 1110–1116.
15. Harrison (1987) Br J Urol.
16. Hyman M.J. Groutz A. Blaivas J.G. (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166: 550–552; discussion 553.
17. Jacobsen S.J. Girman C.J. Lieber M.M. (2001) Natural history of benign prostatic hyperplasia. Urology 58: 5–16; discussion 16.
18. Kaplan S.A. (2006a) Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices. Rev Urol 8: 14–22.
19. Kaplan S.A. (2006b) Update on the American Urological Association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol 8(Suppl. 4): S10–S17.
20. Kaplan S.A. Roehrborn C.G. Rovner E.S. Carlsson M. Bavendam T. Guan Z. (2006) Tolterodine and Tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296: 2319–2328.
21. Kaplan S.A. Walmsley K. Te A.E. (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273–2275.
22. Kaplan S.A. Walmsley K. Te A.E. (2008) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 179: S82–S85.
23. Lee J.Y. Kim H.W. Lee S.J. Koh J.S. Suh H.J. Chancellor M.B. (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94: 817–820.
24. Marks L.S. Roehrborn C.G. Andriole G.L. (2006) Prevention of benign prostatic hyperplasia disease. J Urol 176: 1299–1306.
25. McConnell J.D. Bruskewitz R. Walsh P. Andriole G. Lieber M. Holtgrewe H.L. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338: 557–563.
26. McConnell J.D. Roehrborn C.G. Bautista O.M. Andriole G.L. Jr Dixon C.M. Kusek J.W. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398.
27. McVary K.T. Roehrborn C.G. Avins A.L. Barry M.J. Bruskewitz R.C. Donnell R.F. (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185: 1793–1803.
28. Roehrborn C.G. Siami P. Barkin J. Damiao R. Major-walker K. Morrill B. Montorsi F. (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179: 616–621; discussion 621.
29. Sibley G.N. (1984) A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J Physiol 354: 431-443.
30. Woo H.H. Chin P.T. McNicholas T.A. Gill H.S. Plante M.K. Bruskewitz R.C. Roehrborn C.G. (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108: 82–88.